Search Result

Results for "

HIV-1 integrase strand transfer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HIV (12) HIV Integrase (12) iGluR (1) Isotope-Labeled Compounds (2) Reference Standards (1)
By Research Areas:	Infection (11) Inflammation/Immunology (2) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: HIV Integrase HIV HIV Protease Microsomal Triglyceride Transfer Protein (MTP)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W010937

1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide BMIM-TFSI; BMI-TFSI	HIV HIV Integrase	Infection
1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide (compound 8) is an **HIV-1 integrase** inhibitor that effectively inhibits both the 3'-processing (3'-P) and strand transfer (ST) steps of the integration reaction. 1-Butyl-3-methylimidazolium bis(trifluoromethylsulfonyl)imide can be utilized in HIV-1 research .

HY-13269

BMS-707035 1 Publications Verification	HIV HIV Integrase	Infection Inflammation/Immunology
BMS-707035 is a potent orally active **HIV-1 integrase strand transfer inhibitor (INSTI). BMS-707035 has enzyme inhibitory with an IC₅₀** value of 3 nM. BMS-707035 also has weak CYP inhibiton and antiviral activity. BMS-707035 can be used for the research of human immunodeficiency virus-1 (HIV-1) .

HY-13238

Dolutegravir Maximum Cited Publications 25 Publications Verification S/GSK1349572	HIV Integrase HIV	Infection
Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable **HIV integrase strand transfer inhibitor with an IC₅₀** of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

HY-13238A

Dolutegravir sodium Maximum Cited Publications 25 Publications Verification S/GSK1349572 sodium	HIV Integrase HIV	Infection
Dolutegravir sodium (S/GSK1349572 sodium) is a highly potent and orally bioavailable **HIV integrase strand transfer inhibitor with an IC₅₀** of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir sodium (S/GSK1349572 sodium) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir sodium (S/GSK1349572 sodium) retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

HY-13238S1

Dolutegravir-d3 S/GSK1349572-d₃	Isotope-Labeled Compounds HIV Integrase HIV	Infection
Dolutegravir-d₃ is the deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC₅₀ of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

HY-13269R

BMS-707035 (Standard)	HIV HIV Integrase	Infection Inflammation/Immunology
BMS-707035 (Standard) is the analytical standard of BMS-707035. This product is intended for research and analytical applications. BMS-707035 is a potent orally active HIV-1 integrase strand transfer inhibitor (INSTI). BMS-707035 has enzyme inhibitory with an IC50 value of 3 nM. BMS-707035 also has weak CYP inhibiton and antiviral activity. BMS-707035 can be used for the research of human immunodeficiency virus-1 (HIV-1) .

HY-108820

HIV-1 integrase inhibitor 4	HIV Integrase HIV	Infection
HIV-1 integrase inhibitor 4 is a **HIV-1 integrase strand transfer (INST) inhibitor with an IC₅₀** of 3.7 nM.

HY-108817

HIV-1 integrase inhibitor 3	HIV Integrase HIV	Infection
HIV-1 integrase inhibitor 3 is a **HIV-1 integrase strand transfer (INST) inhibitor with an IC₅₀** of 2.7 nM.

HY-N7330

Integracin B	HIV Integrase HIV	Infection
Integracin B is a potent dimeric alkyl aromatic inhibitor of **HIV-1 integrase** discovered from the screening of fungal extracts using an in vitro assay. Integracin B inhibits both coupled and strand transfer activity of HIV-1 integrase .

HY-13238S2

Dolutegravir-d5 S/GSK1349572-d₅	Isotope-Labeled Compounds HIV Integrase HIV	Infection
Dolutegravir-d₅ is deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC₅₀ of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

HY-13238R

Dolutegravir (Standard) S/GSK1349572 (Standard)	Reference Standards HIV Integrase HIV	Infection
Dolutegravir (Standard) is the analytical standard of Dolutegravir. This product is intended for research and analytical applications. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable **HIV integrase strand transfer inhibitor with an IC₅₀** of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

HY-I0096

Indole-2-carboxylic acid	iGluR HIV HIV Integrase	Neurological Disease
Indole-2-carboxylic acid (I2CA) is a competitive antagonist of the glycine site of the NMDA receptor (K_i=15 μM, 5-fluoro-I2CA) and an inhibitor of **HIV-1 integrase. Indole-2-carboxylic acid is selective for the glycine site of the NMDA receptor** and blocks the enhancement of NMDA receptor by competitively inhibiting the binding of glycine to the NMDA receptor. Indole-2-carboxylic acid can also inhibit the strand transfer activity of HIV-1 integrase by chelating Mg ²⁺ at the active site of integrase and interacting with the hydrophobic cavity. Indole-2-carboxylic acid can be used in the study of neurological diseases (such as stroke, epilepsy) and HIV-1 infection .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-I0096

Indole-2-carboxylic acid	Structural Classification Ketones, Aldehydes, Acids Source classification Endogenous metabolite	iGluR HIV HIV Integrase
Indole-2-carboxylic acid (I2CA) is a competitive antagonist of the glycine site of the NMDA receptor (K_i=15 μM, 5-fluoro-I2CA) and an inhibitor of **HIV-1 integrase. Indole-2-carboxylic acid is selective for the glycine site of the NMDA receptor** and blocks the enhancement of NMDA receptor by competitively inhibiting the binding of glycine to the NMDA receptor. Indole-2-carboxylic acid can also inhibit the strand transfer activity of HIV-1 integrase by chelating Mg ²⁺ at the active site of integrase and interacting with the hydrophobic cavity. Indole-2-carboxylic acid can be used in the study of neurological diseases (such as stroke, epilepsy) and HIV-1 infection .

HY-N7330

Integracin B	Infection Microorganisms Classification of Application Fields Source classification Phenols Polyphenols Disease Research Fields	HIV Integrase HIV
Integracin B is a potent dimeric alkyl aromatic inhibitor of **HIV-1 integrase** discovered from the screening of fungal extracts using an in vitro assay. Integracin B inhibits both coupled and strand transfer activity of HIV-1 integrase .

Cat. No.	Product Name	Chemical Structure

HY-13238S1

Dolutegravir-d3
Dolutegravir-d₃ is the deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC₅₀ of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

Dolutegravir-d3

Dolutegravir-d₃ is the deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC₅₀ of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

HY-13238S2

Dolutegravir-d5
Dolutegravir-d₅ is deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC₅₀ of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

Dolutegravir-d5

Dolutegravir-d₅ is deuterium labeled Dolutegravir. Dolutegravir (S/GSK1349572) is a highly potent and orally bioavailable HIV integrase strand transfer inhibitor with an IC₅₀ of 2.7 nM for HIV-1 integrase-catalyzed strand transfer. Dolutegravir (S/GSK1349572) inhibits HIV-1 viral replication with an IC₅₀ of 0.51 nM in peripheral blood mononuclear cells. Dolutegravir retains a high potency against the HIV-1 Y143R, N155H, and G140S/Q148H mutants (EC₅₀=3.6-5.8 nM) .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks